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Abstract
Background/Aims: Pim-1 is a serine/threonine kinase that is highly expressed in the heart, 
and exerts potent cardiac protective effects through enhancing survival, proliferation, 
and regeneration of cardiomyocytes. Its myocardial specific substrates, however, remain 
unknown. In the present study, we aim to investigate whether Pim-1 modulates myofilament 
activity through phosphorylation of cardiac troponin I (cTnI), a key component in regulating 
myofilament function in the heart. Methods: Coimmunoprecipitation and immunofluorescent 
assays were employed to investigate the interaction of Pim-1 with cTnI in cardiomyocytes. 
Biochemical, site directed mutagenesis, and mass spectrometric analyses were utilized to 
identify the phosphorylation sites of Pim1 in cTnI. Myofilament functional assay using skinned 
cardiac fiber was used to assess the effect of Pim1-mediated phosphorylation on cardiac 
myofilament activity. Lastly, the functional significance of Pim1-mediated cTnI in heart disease 
was determined in diabetic mice. Results: We found that Pim-1 specifically interacts with 
cTnI in cardiomyocytes and this interaction leads to Pim1-mediated cTnI phosphorylation, 
predominantly at Ser23/24 and Ser150. Furthermore, our functional assay demonstrated that 
Pim-1 induces a robust phosphorylation of cTnI within the troponin complex, thus leading to 
a decreased Ca2+ sensitivity. Insulin-like growth factor 1 (IGF-1), a peptide growth factor that 
has been shown to stimulate myocardial contractility, markedly induces cTnI phosphorylation 
at Ser23/24 and Ser150 through increasing Pim-1 expression in cardiomyocytes. In a high-
fat diabetic mice model, the expression of Pim1 in the heart is significantly decreased, 
which is accompanied by a decreased phosphorylation of cTnI at Ser23/24 and Ser150, 
further implicating the pathological significance of the Pim1/cTnI axis in the development of 
diabetic cardiomyopathy. Conclusion: Our results demonstrate that Pim-1 is a novel kinase 
that phosphorylates cTnI primarily at Ser23/24 and Ser150 in cardiomyocytes, which in turn 
may modulate myofilament function under a variety of physiological and pathophysiological 
conditions.
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IntroductionPim-1 is a highly conserved serine/threonine kinase that belongs to the calmodulin-dependent protein kinase related group and prefers to phosphorylate the consensus 
sequence (K/R)-(K/R)-(K/R)-X-(S/T)-X [1]. It is originally identified as a cellular oncogene that inhibits apoptosis and promotes proliferation [1]. Recently, accumulating evidence suggests that Pim-1 plays a pivotal role in protecting heart function from ischemia induced damage and cardiac hypertrophy [2, 3], as well as protecting mitochondrial integrity in cardiomyocyte [4]. Moreover, Pim-1-engineered cardiac progenitor cells dramatically improve the cardiac function after myocardial infarction [5, 6]. Systemic delivery of human Pim-1 via cardiotropic adeno-associated virus serotype-9 improves diabetic cardiomyopathy by induction of prosurvival signaling [7]. Furthermore, Pim-1 has been shown to promote cardiomyocyte survival and protect heart muscles from ischemic damage downstream of Akt through regulating expression of anti-apoptotic proteins and calcium channels [8]. Notably, Pim-1 maintains cardiomyocyte contractility by increasing Ca2+ transient amplitude and percentage of cell shortening in isolated cardiomyocyte [8]. However, the molecular mechanisms underlying Pim-1-mediated cardiac contractility still remain unclear.Cardiac troponin complex has three major components, cardiac troponin I (cTnI), Troponin T (TnT), and Troponin C (TnC) [9, 10]. cTnI is the inhibitory unit that interacts 
with the major proteins present in the sarcomeric thin ﬁlament, including actin, cTnC, 
α-tropomyosin (α-TM), and cTnT [11]. These interactions reveal the pivotal roles of cTnI in regulating heart muscle crossbridge kinetics and contraction in response to changes of intracellular Ca2+ concentrations [12]. Phosphorylation of specific serine and threonine residues on cTnI by several different kinases represents a major physiological mechanism for 
alteration of myofilament properties. For example, cAMP-dependent protein kinase (PKA) mediates phosphorylation of the two serine residues (Ser-23/24) in the unique N-terminal 
domain of cTnI, leading to a reduction in myoﬁlament Ca2+ sensitivity and an increase in crossbridge cycling rate by reducing the Ca2+-binding afﬁnity of cTnC [13]. Likewise, PKD1 
phosphorylates cTnI at Ser-23/24, resulting in desensitization of the myofilament response to Ca2+ as well as an increase in cross-bridge kinetics [14, 15]. Another important protein kinase family, protein kinase C (PKC) is found to phosphorylate cTnI at Ser-23/24, Ser-43/45, and Thr144 residues [16]. Phosphorylation of the Ser-43/45 sites depresses the maximum tension and crossbridge kinetics, which is in contrast to phosphorylation of Ser-23/24 [17]. Moreover, the effect of phosphorylation at Ser-43/45/Thr144 dominates the effects of phosphorylation at Ser-23/24 [18]. Other kinases such as P21-activated kinases (PAK) have been found to cause phosphorylation of cTnI at Ser-149, which results in an increase 
in myofilament Ca2+ sensitivity [19]. More recently, 5’-AMP kinase (AMPK) has been shown to induce an increase in Ca2+ responsiveness of the myofilaments and blunt PKA-dependent function through phosphorylation of Ser-150 of cTnI [20-22]. Importantly, by using mass spectrometric (MS) approaches, Zhang et al. demonstrated that there is a depression in phosphorylation at cTnI-Ser23/24 but an increase in phosphorylation of cTnI-Ser43/45 in human ischemic and dilated cardiomyopathy [23]. Thus, alteration of cTnI phosphorylation levels has a great clinical relevance that may shed light on the discovery of novel therapeutic targets of heart failure.Pim-1 is implicated in regulating cardiomyocyte contractility and calcium transient, the 
role of Pim-1 in modulating cardiac myofilament activity, however, remains largely unknown 
[8]. In the present study, we for the first time identified Pim-1 as a novel kinase that specifically interacts with cTnI and causes cTnI phosphorylation at Ser23/24 and Ser150, thus leading to a reduced Ca2+ sensitivity of contractile regulation. Furthermore, we demonstrated that IGF-1, a peptide growth factor that has been shown to stimulate myocardial contractility and 
protects cardiac injury [24, 25], significantly induces cTnI phosphorylation at Ser23/24 and Ser150 in a Pim-1 dependent manner in cardiomyocytes. Collectively, these results suggest that cTnI phosphorylation by Pim-1 may represent a novel mechanism underlying the Pim-1-mediated protective effects in the heart.
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Materials and Methods
Cell culture
Human embryonic kidney cells HEK293T and Ad293 cells (ATCC) were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% FBS (GIBCO), 1% penicillin/streptomycin (GIBCO) in a 
humidified atmosphere of 5% CO2 at 37°C.
Animal model of diabetes
Wild-type (WT) and db/db mice on C57BLK6/J background were obtained from Jackson Laboratory. Animals were fed either regular chow diet or high fat diet (HF) from 8 week old to 16 week old as described 
previously [26]. Mice were sacrificed by inhalation of CO2 for the collection of the heart. This study was 
reviewed and approved by the Institutional Animal Care and Use Committee at Thomas Jefferson University.
Isolation of adult rat ventricular myocytes
Ventricular myocytes were isolated from the hearts of adult male Sprague-Dawley rats by collagenase-based enzymatic digestion, as described previously [15]. In brief, hearts were excised and perfused for 5 
min with modified HEPES-Krebs solution (pH 7.3 at 37°C) containing (in mmol/L) NaCl 130, MgCl2 4.5, NaH2PO4 0.4, CaCl2 0.75, HEPES 4.2, taurine 20, creatine 10 and glucose 10. The buffer was saturated with 
95% O2/5% CO2 (pH 7.4, 37°C). Hearts were then consecutively retrogradely perfused with Ca2+-free HEPES-
Krebs solution containing 100 μmol/L EGTA (4 min) and HEPES-Krebs solution containing 100 μmol/L CaCl2 and 1 mg/mL type II collagenase (Worthington, Lakewood, USA). Hearts were then removed from the perfusion apparatus, the ventricles cut into small pieces, and isolated myocytes were separated from 
undigested ventricular tissue by filtering through nylon gauze, and the latter was incubated in 30 mL of the collagenase solution for a further 8 min. This step was repeated, thereby generating three isolated myocyte fractions. In each fraction, myocytes were allowed to settle into a loose pellet and the supernatant was 
removed and replaced with HEPES-Krebs solution containing 1 % BSA and 500 μmol/L CaCl2. Myocytes 
were again allowed to settle, the supernatant removed and the cells finally pooled and resuspended in 30 
mL of HEPES-Krebs solution containing 1 mmol/L CaCl2. The pooled isolated myocytes were pelleted by brief centrifugation at 50g and washed at room temperature.
Co-immunoprecipitation of cTnI and Pim-1 in HEK293T cells and heart tissuesHEK293T cells were transiently transfected with Flag-tagged cTnI and Myc-tagged Pim-1 expression plasmids using PEI following our standard protocol for 48 hours. HEK293T cells or rat heart tissues were 
lysed or homogenized in a buffer containing 50 mM Tris/HCl (pH 8.0), 1% Nonidet P40, 150 mM NaCl and protease inhibitors. Co-immunoprecipitation of cTnI and Pim-1 was performed as described previously [27]. The following antibodies and beads were used for detection and immunoprecipitation: rat polyclonal 
anti-Myc antibody (Genescript), mouse monoclonal anti-FLAG antibody (Genescript), rabbit monoclonal anti-Pim1 antibody (Santa Cruz) and rabbit monoclonal anti-TnI antibody (Cell Signaling), anti-c-Myc-
agarose affinity gel (Sigma) and anti-FLAG M2-agarose (Sigma).
Immunoblotting
Cell lysates were made using RIPA buffer (Thermo Scientific) containing 25 mM Tris-HCl pH 7.6, 150 
mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS and proteinase inhibitor cocktail containing 2 mM 
PMSF, 20 μg/mL aprotinin, 10 μg/mL leupeptin. After 1 h extraction with rocking at 4°C, insoluble material 
was removed by centrifugation. Supernatants were resolved by SDS-PAGE, and transferred to nitrocellulose 
membranes (Bio-Rad), which were blocked with 5% non-fat milk in PBS with 0.1% Tween 20 (PBS/T) 
and then incubated with diluted antibodies overnight at 4°C with agitation. After washing with PBS/T for 
three times, membranes were incubated with appropriate secondary antibodies (Thermo Scientific). Blots 
were visualized on an Odyssey Imaging System (LI-COR) as we described previously [28]. The following antibodies were used for detecting phosphorylated TnI: anti-phospho-Troponin I (Cardiac) (Ser23/24) antibody (Cell Signaling), Troponin I Type 3 (cardiac) [p-Ser150] Antibody (Ser150) antibody (Novus).
Immunofluorescent staining
The myocytes cultured on the laminin-coated glass coverslips were fixed with 4% paraformaldehyde for 
10 min, washed three times in PBS, and then permeabilized with 0.25%Triton-X100 for 15 min. Following a 
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blocking step with 10% of goat serum in PBS for 60 min, the cardiomyocyte were co-immunostained with a rabbit monoclonal primary antibody against cTnI (1:200, Cell Signaling) and a mouse monoclonal antibody 
against Pim-1 (1:200, Santa Cruz) for overnight at 4°C. After washing three times in PBS for 10 min, cells were stained with TRITC-conjugated anti-rabbit IgG and FITC-conjugated anti-mouse IgG second antibodies 
at 1:250 (Invitrogen, USA), respectively, at 37 ºC for 2 h and then were rinsed three times with PBS. Cell 
nuclei were stained with DRAQ5. The stained cells were observed by laser-scanning confocal microscopy 
(Leica, Heidelberg, Germany).
In vitro phosphorylation assays
Recombinant human cTnI, human troponin complex (Prospec, East Brunswick, NJ), skinned myocyte 
were incubated with active recombinant Pim-1 (EMD Millipore) and 100 μmol/L 32P-ATP (PerkinElmer) in 
a kinase assay buffer containing (in mmol/L) Tris-HCl (pH 7.5) 25, beta-glycerophosphate 5, dithiothreitol 
(DTT) 2, Na3VO4 0.1, MgCl2 10 for up to 120 min at 37 °C as we described previously [28]. The reaction was 
terminated by the addition of 0.5 volumes of 3×Laemmli sample buffer and incubated at 95 °C for 5 min, and 
then resolved by SDS/PAGE (12% gels) and autoradiography. For western blot analysis, recombinant cTnI or its mutants was phosphorylated by incubating with active Pim-1 in the presence of non-radiolabelled 
ATP (500 μmol/L).
Identification of phosphorylation sites by mass spectrometry
Peptides contained Ser23/24 and Ser150 (APIRRRSSNYRA and TLRRVRISADAM) were synthesized by Genscript. Peptides were incubated with active Pim-1 in the presence of non-radiolabelled ATP (500 
μmol/L) at 30 °C for 60 min. For peptide mass spectrometry analysis of the tryptic digestion products, 50 μL 
of the solution was analyzed by LC-MS, using an HPLC system (Series 1100, Agilent Technologies) coupled to 
an electrospray ionization mass spectrometer (Finnigan LCQ Advantage MAX, Thermo Electron Corp.). For 
HPLC separation of the peptides, a CC 250/4 Nucleosil 100-5 C18 Nautilus column (Macherey-Nagel GmbH) 
was used, with a linear gradient over 60 min of 0-65 % solution B in solution A (solution A, 0.1 % formic acid 
in water; solution B, 0.1 % formic acid in acetonitrile). Mass spectra were analyzed using Finnigan Xcalibur software (Thermo Electron Corp.) and the peptide masses assigned, using ExPASy software.
Expression of cTnI mutants and immunoprecipitation kinase assay
Mutants of Flag-tagged cTnI plasmids (Ser23/24→Ala23/24, TCC/TCC→GCC/GCC; Ser42/44→Ala42/44, 
TCC/TCG→GCC/GCG; Thr143→Ala143, ACC→GCC; Ser150→Ala150, TCT→GCT) were generated using Quick-Change II kit as described by the manufacturer (Agilent). Wild type or mutated plasmids were transiently transfected into HEK293T cells and lysed with IP lysis buffer. Immunoprecipitation was performed as described previously [27]. In brief, cell lysates were incubated with anti-Flag M2-agarose (Sigma) overnight at 4°C with rotation. Agarose beads were centrifuged for 30 sec at 4°C, followed by three times washing 
with 500 μl of 1X kinase buffer. The beads pellets were resuspended in 20μl 1X kinase buffer supplemented 
with 100 μmol/L 32P-ATP (PerkinElmer) and active Pim-1 protein and then incubated 60 min at 30°C. The 
reaction was terminated by the addition of 0.5 volumes of 3×Laemmli sample buffer and incubated at 95 °C 
for 5 min, and was then resolved by SDS/PAGE (12% gels) and autoradiography.
Skinned myocyte preparation
Skinned myocyte was prepared as described previously with modifications [21]. Hearts from Sprague-
Dawley rats were excised and immersed in ice-cold relaxing solution, containing (in mmol/L) EGTA 10, 
2-[N,N-Bis(2-hydroxyethyl)amino] ethanesulfonic acid (BES) 100, potassium proprionate 55, ATP 5, creatine phosphate 10, free Mg2+ 1, and protease inhibitor. The myocardial tissue was homogenized in a Waring blender (~10 s in ice cold relaxing solution) and, following centrifugation (1400 rpm, 1 min), the 
myocyte pellet was re-suspended in Triton X-100 (1 % v/v in relaxing solution) for 10 min, to disrupt lipid membranes. Following two further cycles of similar centrifugation and re-suspension, the myocyte pellet was washed, re-suspended and kept in ice-cold relaxing solution, until used for in vitro phosphorylation assays or mechanical measurements.
Functional studies in skinned myocyte fragments
Rat skinned cardiac muscle fibers were pre-incubated with or without 0.1 mg/ml Pim1 in a relaxing solution for 30 min. Force measurement was performed as previously described [14]. For mechanical 
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measurements, myocyte fragments were clamped to a sensitive force transducer (Model 403A, 200 mV/
mg, Cambridge Technology, Inc.) and a high-speed length controller (Model 308B, Aurora Scientific, Inc.) at either end. All mechanical experiments were performed at 18 °C. Sarcomere length was acquired (240 
Hz CCD camera) and analyzed using commercial software (IonOptix Corp.). The sarcomere length was set 
to ~2.0 μm in relaxing solution for all functional measurements. Solution changes were made using a fast 
stepper motor attached to 2 parallel capillary tubes (Model SF-77B Perfusion Fast-Step, Warner Instrument Corp.). pClamp software (Axon Instruments) was used to trigger the stepper motor for solution changes or to impose rapid length changes on the myocyte fragment. Force and length signals were recorded on a computer using a 12-bit analog/digital board, sampling at 2 kHz. Skinned myocytes were activated in solutions (pH 7.0) containing a Ca2+ concentration ranging between 10-9 (pCa 9.0; relaxing solution, composition as given above) and 10-4.5 mol/L (pCa 4.5; maximal Ca2+ activating solution), to measure the Ca2+ sensitivity of myofilaments.
Statistical analyses
Data are expressed as means ± SE. The statistical significance of differences was assessed by Student’s 
t-test or analysis of variance (ANOVA) with Bonferroni’s post hoc test, as appropriate; a value of P < 0.05 was 
considered statistically significant.
Results
Interaction of Pim-1 with cTnITo elucidate the mechanism underlying the regulation of cardiac contractility by Pim-1 [8, 29], we attempted to investigate whether the cardio-protective kinase Pim-1 interacts with cTnI. In this regard, Myc-tagged human Pim-1 and Flag-tagged human cTnI plasmids were co-transfected into HEK293T cells, co-immunoprecipitation was then performed. As shown in Fig.  1A, immunoprecipitation of Myc-tagged Pim-1 led to co-precipitation of 
FLAG-tagged cTnI. Similarly, immunoprecipitation of Flag-tagged cTnI resulted in the co-immunoprecipitation of Myc-tagged Pim-1 (Fig. 1A). To determine whether there is an endogenous interaction of cTnI and Pim-1 in cardiomyocytes, we performed co-immuno-precipitation with anti-Pim-1 antibody using mouse heart ly-
sates. As shown in Fig.  1B, cTnI co-precipitated with the anti-Pim-1 antibody, but not with the nonimmune IgG. To investigate the intracellular localization of this interaction, we performed 
immunofluorescent staining in adult mouse cardiomyocytes. 
Immunofluorescent microscopy showed a strong colocalization of Pim-1 and cTnI in the sarco-mere of cardiac cells (Fig.  1C). Together, these results indicate that Pim-1 interacts with cTnI in cardiomyocytes under physi-ological conditions.
Fig. 1. Interaction of Pim-1 with cTnI. (A). HEK293T cells were co-transfected with Flag-cTnI and Myc-Pim-1. Co-immunprecipi-tation were performed by using anti-Flag or anti-Myc antibodies 
and then analyzed by western blot. (B). Adult mouse heart tis-sue samples were extracted and immunoprecipitated with either anti-Pim-1 antibody or control IgG and then analyzed by western blot. (C) Fixed adult mouse cardiomyocyte were stained with anti-
Pim-1 and anti-cTnI antibodies and then processed for fluorescent staining analysis.
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Pim-1 phosphorylates cTnI 
primarily at serine 23/24 
and serine 150Since Pim-1 is a serine/threonine kinase, the interaction of Pim1 with cTnI prompted us to investigate whether cTnI is a good substrate of Pim-1. To test this hypothesis, in vitro phos-phorylation assays were carried 
out using purified recombinant human cTnI as substrate, which was incubated with active Pim-1 
in the presence of [γ-32P] ATP. As 
shown in Fig.  2A and 2B, incuba-tion of recombinant Pim-1 with cTnI resulted in a robust phos-phorylation of cTnI in a time and dose-dependent manner. To determine the phosphorylation kinetics of troponin complex by Pim-1, the time course of Pim-1-induced phosphorylation of the reconstituted troponin (Tn) complex was determined in an 
in vitro kinase assay. Interest-ingly, Pim-1 phosphorylates cTnI in the troponin complex in a time-dependent manner, while TnT was also phosphory-lated by Pim-1 in the Tn com-plex (Fig.  2C). Taken together, these results suggest that cTnI is a good substrate of Pim-1 ki-nase.
Because Pim-1 prefer-entially phosphorylates the consensus sequence (K/R)-(K/R)-(K/R)-X-(S/T)-X [30], and phosphorylation of several serine/threonine sites in cTnI has been reported to play im-portant roles in regulation of cardiac contraction/relaxation. We attempted to map the Pim1-induced phosphorylation sites in cTnI by a site-directed mu-tagenesis of Ser (S) to Ala (A) [28]. Mammalian expression plasmids bearing Flag-tagged S23/24A, S42/44A, T143A and S150A mutants were construct-ed and then transfected into HEK293T cells. 48 hours after 
Fig. 2. cTnI is phosphorylated by Pim-1 at Ser-23/24 and Ser-150. Recombinant cTnI was incubated with active Pim-1 in the pres-
ence of [γ-32P]ATP for different times (A) or different doses (B). Phosphorylation was detected by autoradiography and cpm was 
counted. (C), The Tn complex was incubated with 0.5 μg of active 
Pim-1 for different time points as indicated in the presence of [γ 
-32P]ATP in an in vitro phosphorylation assay. Both the autora-diograph (left panel) and the Coomassie-stained gel (right panel) are shown.
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Fig. 3. Identification of Pim-1-induced phosphorylation sites in 
cTnI. (A), Autoradiograph of 12% SDS-polyacrylamide gel showing the phosphorylation levels of wild-type and different mutants of cTnI by Pim-1. Expression vectors bearing WT and different mutants of cTnI were transfected into HEK293 cells. 48hr after transfection, overexpressed protein was immunoprecipitated by anti-Flag an-tibody and then subjected to an in vitro kinase in the presence of 
active Pim-1 and [γ -32P]ATP. ** P<0.01 vs WT group. (B). Autora-
diograph of 12% SDS–polyacrylamide gel showing Pim-1-induced phosphorylation levels of human cTnI containing either wild-type or combined mutation of cTnI in an in vitro kinase assay. Expression vectors bearing WT and various mutants of cTnI were transfected into HEK293 cells. 48hr after transfection, overexpressed protein was immunoprecipitated by anti-Flag antibody and then subjected 
to an in vitro kinase in the presence of active Pim-1 and [γ -32P]ATP. 
** P<0.01 vs WT group. (C). cTnI was incubated with active Pim-1 in the presence of ATP and Pim-1, phospho-ser23/24 and ser-150 was detected by western blot and quantitated by densitometric analysis.
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transfection, overexpressed proteins were immunopre-cipitated by anti-Flag anti-body and then used for an 
in vitro kinase assay in the presence of active Pim-1 
and [γ-32P]-ATP. As shown in Fig.  3A, TnI S23/24A 
mutant significantly abol-ished Pim-1-mediated cTnI phosphorylation by ap-
proximately 80%, whereas S150A mutant caused a ~60 
% reduction in cTnI phos-phorylation, suggesting that Pim-1 phosphorylates cTnI primarily at Ser-23/24 and Ser-150. Furthermore, a S23/24/150A triple mu-tant was generated and the mutant protein was overex-pressed and immunoprecipitated for an in vitro phosphorylation assay. No-tably, triple mutant of S23/24/150A almost completely abolished Pim-1-induced cTnI phosphorylation (Fig. 
3B). Moreover, Pim-1 induced in vitro phosphorylation of cTnI was detected by western blot using anti-phospho-Ser/23/24 and phosphor-Ser150 spe-
cific antibodies. As shown in Fig.  3C, both Ser-23/24 and Ser-150 of cTnI were robustly phosphorylated by Pim-1 in a dose-dependent manner.
Verification of the phosphorylation 
sites by MALDI–TOF-MS
To further confirm the Pim-1-in-duced phosphorylation sites in cTnI, two peptides derived from cTnI span-ning the potential phosphorylation residues of Ser23/24 and Ser150 were synthesized, respectively, and then treated with active pim1 protein. Phos-phorylation of peptides was analyzed by the high resolution mass spectrom-
etry. As shown in Fig.  4A and 4B, both 
peptides were efficiently phosphory-lated at Ser23/24 and Ser150 by Pim1, further indicating that Pim1 could potentially phosphorylate cTnI at Ser23/24 and Ser150.
Pim-1 regulates cardiac myofilament function
To determine the effect of Pim1-induced cTnI phosphorylation on cardiac myofilament 
activity, we first investigated whether Pim1 phosphorylates cTnI Ser23/24 and Ser150 
Fig. 5. Effects of Pim-1-mediated phosphorylation on Ca2+-sensitive tension development in skinned myocytes. (A). Pim-1-mediated cTnI phosphorylation in skinned myo-cyte preparations, as detected by western blot and quan-titated by densitometric analysis. Equal protein loading is 
indicated by actin on coomassie-stained gels. ** P<0.01 vs 
non-treatment group. (B). Relative maximum force devel-opment by skinned myocytes in the presence or absence of Pim-1 incubation. (n=5 per group). (C). Tension-pCa re-lationship under control and after Pim-1-mediated phos-phorylation in the presence of solutions at pCa 9.0 to 4.5 (n=5 per group).
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residues in skinned fibers from the adult rat left ventricle. As expected, there was a significant increase in the phosphorylation of Ser23/24 and Ser150 after a 60-minute exposure of 
the skinned fiber preparation to active Pim1, indicating that cTnI is a natural substrate of Pim1 and Pim1 may regulate Ca2+ sensitivity in skinned myocardial preparations (Fig.  5A). 
Then, we determined whether Pim-1-mediated cTnI phosphorylation affects myofilament contractility and calcium selectivity in skinned myocytes from the adult rat left ventricle. 
Although there was no significant difference between the control and Pim1-treated groups 
in maximum force and Hill coefficient (nH) (Fig.  5B), Pim1-mediated phosphorylation of 
cTnI significantly reduced the Ca2+ sensitivity of skinned myocardial fibers, resulting in a 
rightward shift of the force-pCa curve (Fig.  5C). As shown in Fig.  5D, pCa at 50% maximal 
tension (pCa50) was 5.912 ± 0.029 in the control group (n=4) and 5.760 ± 0.010 in the Pim1-treated group (n=5; P<0.05), suggesting that there was a reduction of Ca2+ sensitivity 
of Pim1-modified skinned fiber preparations.
IGF-1 phosphorylates cTnI through inducing expression of Pim-1 in cardiomyocytesInsulin like growth factor 1 (IGF-1) has been shown to stimulate cardiac growth and contractility and exert protective effects in the heart, although the mechanism of this effect still remains elusive [25]. Interestingly, IGF has recently been shown to potently induce Pim1 expression in the heart [8], which prompted us to speculate that IGF-1 may regulate cardiomyocyte contractility via Pim-1-induced cTnI phosphorylation. To test this hypothesis, rat ventricle cardiomyocytes were stimulated with IGF-1 and phosphorylation of cTnI at Ser-23/24 and Ser-150 were then determined by western blot. Indeed, consistent with a previous report [8], IGF-1 treatment of cardiomyocytes markedly induces Pim-1 expression, which parallels the increased phosphorylation of cTnI at Ser23/24 and Ser150 
in cardiomyocytes (Fig.  6A and 6B). To further determine the molecular signaling pathway (s) involved in IGF-1-induced cTnI phosphorylation, several pharmacological inhibitors of protein kinases were utilized. As shown in Fig.  6C, pretreatment of cardiomyocytes with PKA inhibitor H89 barely affected IGF-I-induced cTnI phosphorylation, while inhibition 
of AKT pathway with LY294002 partially, but significantly, blocked IGF-1-induced cTnI 
phosphorylation. Importantly, pretreatment of cardiomyocytes with SMI-4a, a Pim-1 specific 
Fig. 6. Pim-1 is involved in IGF-1-induced cTnI phosphorylation in cardiomyocytes. (A). Rat ventricular cardiomyocytes were stimulated with IGF-1 (20 ng/ml) at different time points (A) and doses for 60 min 
(B), phosphorylation levels of cTnI at Ser23/24 and Ser150, total cTnI, and Pim-1 were detected by western 
blot and quantitated by densitometric analysis. * P<0.05; ** P<0.01 vs basal level. n=3. (C). Cardiomyocytes 
were treated with SMI-4a (10 µM), LY294002 (30 μM) or H89 (10 µM) for 1 hr, followed by stimulating with IGF-1 (20 ng/ml) for 2 hr, phosphorylation levels of cTnI at Ser23/24 and Ser150, total cTnI, and Pim-1 were 
detected by western blot and quantitated by densitometric analysis. * P<0.05 vs. CTL. # P<0.05 vs. IGF-1 
treated group. SMI-4a, Pim-1 inhibitor; LY294002, PI3K inhibitor; H89, PKA inhibitor.
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inhibitor [30], almost completely blocked IGF-1-induced cTnI phosphorylation, suggesting that IGF-1-induced cTnI phosphorylation in cardiomyocytes is Pim-1 dependent.
Implication of the Pim1/cTnI axis in diabetic cardiomyopathyOur previous studies have shown that the expression of Pim-1 is dramatically downregulated in diabetic mouse heart tissues [30]. Furthermore, the cardiac contractility 
and cTnI phosphorylation have been shown to be significantly reduced in diabetic hearts 
[31, 32]. To further substantiate the pathophysiological significance of Pim-1-induced cTnI phosphorylation, we determined whether Pim-1 expression is correlated with cTnI phosphorylation in vivo. In this regard, Pim1 expression and cTnI phosphorylation levels were analyzed in heart homogenates from the diabetic db/db mice fed with a HF and 
their normal controls by western blot analysis. As shown in Fig.  7A and 7B, consistent 
with previous reports [30, 33], the expression of Pim-1 was significantly decreased in the 
diabetic hearts. Likewise, the phosphorylation levels of cTnI at Ser23/24 were markedly 
reduced by approximately 60%, while the phosphorylation of cTnI at Ser150 was slightly, 
but statistically significantly, decreased by approximately 25%, as compared to their normal controls (Fig.  7C). Together, these results suggest that decreased Pim1 expression with a resultant reduction of cTnI phosphorylation in the heart might play important roles in the development of diabetic cardiomyopathy.
Discussion
Covalent modification of cTnI by kinase-mediated phosphorylation is an important 
mechanism in the regulation of thin filament function and thereby the cardiac contractile 
phenotype [11, 12]. Furthermore, altered phosphorylation of cTnI and other myofilament proteins have been shown to contribute causally to the cardiac dysfunction in the transition from compensated hypertrophy to heart failure [23]. Thus far, several protein 
kinases, including PKA, PKC, AMPK, and PKD, have been shown to phosphorylate cTnI and 
regulate myofilament activity [34, 35]. In the present study, we provide the compelling 
evidence implicating Pim-1 as a novel protein kinase that specifically interacts with and phosphorylates cTnI at Ser23/24 and Ser150 in the heart. Indeed, Pim1 and cTnI were found to colocalize in adult cardiomyocytes. The functional consequence of this interaction was 
demonstrated by the ability of Pim1 to induce cTnI phosphorylation and reduce myofilament calcium sensitivity. Indeed, IGF-1, a cardiac protective hormone that has been shown to increase cardiac contractility, increases Pim-1 expression and cTnI phosphorylation cardiac cells. These results suggest that the phosphorylation of cTnI by Pim1 may be an important 
determinant of cardiac myofilament activity.
Recently the pathophysiological roles of Pim-1 in the heart have received a significant 
attention. Both loss- and gain-of-function studies have implicated Pim-1 as an essential kinase in the regulation of cardiomyocyte survival, calcium dynamics, cardiac contractility, 
and mitochondrial function in cardiomyocytes. For instance, cardiac specific overexpression 
Fig. 7. Phosphorylation of cTnI and expression of Pim-1 are decreased in the heart of diabetic mice. (A). Hearts were harvested from control 
C57BLKS/J mice (WT) and db/db mice. cTnI phosphorylation and 
expression of Pim-1 were analysed by western blot. Phosphorylation of cTnI (B) and expression of Pim-1 (C) 
were quantitated by densitometric analysis. * P<0.05; ** P<0.01 vs. with WT mice (Student’s t-test), n = 6.
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of Pim-1 has been shown to decrease infarct size and maintain contractility after myocardial 
infarction  [2, 29], whereas Pim-1 knock out displayed a significant prolongation of calcium decay and the sarcomeric relaxation period and this was accompanied by a decrease in sarcoendoplasmic reticulum Ca2+ATP-ase (SERCA) and sodium-calcium exchanger (NCX) expression [8]. However, it is still unknown whether Pim-1 regulates cardiac 
myofilament function by posttranslational modulation of sarcomere proteins. Indeed, our coimmunoprecipitation and colocalization assays demonstrated a direct binding of Pim-1 with cTnI in cardiac cells, which led us to further investigate whether Pim-1 regulates 
myofilament activity through phosphorylating cTnI. In vitro phosphorylation assays showed that cTnI was robustly phosphorylated by Pim-1 in a time and dose dependent manner. To 
our knowledge, this is the first evidence demonstrating cTnI as a natural substrate of Pim-1 kinase in cardiomyocytes. Furthermore, by applying a site directed mutagenesis strategy and mass spectrometry analysis, we demonstrate that Pim-1 phosphorylates cTnI primarily at Ser23/24 and at Ser150. Furthermore, our in vitro study shows that Pim-1 preferentially phosphorylates cTnI at Ser23/24, and the precise mechanism underlying this process is unknown. We speculate that once Pim-1 binds to cTnI, it will cause a conformational change of cTnI that favors the binding of Pim-1 to the site of Ser23/24. It is well established that 
phosphorylation of cTnI at different sites results in different myofilament function [34]. For 
example, both PKA and PKD have been shown to phosphorylate cTnI at Ser23/24, which resulted in a reduction of Ca2+ sensitivity and acceleration of relaxation and crossbridge cycle kinetics [13-15]. In contrast, p21-activated kinase (PAK), which phosphorylates cTnI at Ser150, has been shown to increase Ca2+ sensitivity [19]. Furthermore, AMPK, which causes a cTnI phosphorylation predominantly at Ser150 as compared to Ser23/24, has been 
shown to increase myofilament Ca2+ sensitivity and prolong cardiac relaxation [21, 22]. In the present study, we herein provided a novel phosphorylation pattern of cTnI as regulated by cardioprotective Pim-1 kinase in the heart. Indeed, our biochemical assays showed that compared to Ser150, Pim-1 preferentially phosphorylates cTnI at Ser23/24, leading to 
a reduction of myofilament Ca2+ sensitivity. It should be noted that the change of cardiac 
myofilament Ca2+ sensitivity does not always correlate with the change of maximum force. 
For example, J van der Velden et al. reported that the maximum force was not significantly changed, but the Ca2+ sensitivity was significantly increased in end-stage failing hearts, which may be attributed to the altered phosphorylation of contractile proteins such as myosin light 
chain 2 (MLC-2) and cTnT [36]. In our study, we also found that in addition to cTnI, cTnT may also function as a substrate of Pim-1 in the heart, which may contribute to the reduced Ca2+ sensitivity and unchanged maximum force.Insulin-like growth factor I (IGF-I) is an important growth factor for cell differentiation and proliferation [37]. In the heart, it has been shown to stimulate cardiac growth and 
increase contractile function [24, 25]. Moreover, cardiac specific overexpression of IGF-1 has 
been shown to reduce myofilament isometric tension and increase cTnI phosphorylation, through a yet unknown mechanism [38]. Recently, IGF-1 has been found to potently induce Pim-1 expression in cardiomyocytes [8]. In our study, we found that Pim-1 increases cTnI phosphorylation at Ser23/24 and Ser150 in a Pim-1- dependent manner in cardiomyocytes. In this regard, our studies provided a novel mechanism by which IGF-1 may exert some of its 
cardioprotective effects through regulation of cTnI phosphorylation and myofilament activity in the heart. Previously, Akt has been shown to be essentially involved in the induction of 
Pim-1 expression by IGF-1 in the heart [8]. Consistent with this finding [8], treatment of 
cardiomyocytes with AKT inhibitor LY294002 markedly, but not completely, blocked IGF-1-induced cTnI phosphorylation, indicating that other molecular pathways may be involved in the IGF-1-induced Pim-1 expression and cTnI phosphorylation in the heart, which warrants further investigation. Indeed, in a diabetic cardiomyopathy model, it has been shown that the changes in myocardial pAkt and Pim-1 levels were not synchronous, with Pim-1 starting to decrease earlier than pAkt [39]. At this point, the molecular mechanism(s) responsible 
for Pim-1 downregulation in DCM remains elusive. Decreased phosphorylation of STAT3 and increased expression of protein phosphatase 2A (PP2A), have been reported to mainly 
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contribute the regulation of Pim-1 expression at transcriptional and posttranslational levels in the diabetic hearts [7, 39].It is well established that diastolic dysfunction is the most prominent defect of diabetic cardiomyopathy, which is characterized by decreased compliance, prolonged myocardial relaxation, and altered intracellular Ca2+ homeostasis [40]. In streptozotocin (STZ) induced 
diabetic cardiomyopathy, reduced SERCA2a expression is still not sufficient to explain the 
contractile deficit [41]. In this study, we found that Pim-1 expression was significantly reduced in diabetic hearts, which is consistent with previous published studies [39]. Moreover, this reduction was accompanied by decreased phosphorylation levels of Ser23/24 and Ser150, suggesting that Pim-1 may represent an important upstream kinase responsible for modulating cTnI phosphorylation in diabetic cardiomyopathy. Indeed, several studies 
have shown that IGF-1 levels are significant reduced under diabetic conditions [42-44]. These results suggest that preservation of IGF-1/Pim-1 pathway in the heart may represent a novel therapeutic strategy to prevent the development of diabetic cardiomyopathy.
ConclusionIn summary, we have shown that Pim-1 is a novel kinase that interacts with cTnI in 
cardiomyocytes. This interaction is relatively specific, as it causes cTnI phosphorylation; it 
is functional, as it leads to a reduction of myofilament Ca2+ sensitivity; and it is physiological, 
as it may mediate the cardioprotective effects of IGF-1 on cardiomyocytes. These findings suggest that Pim-1 may be an important therapeutic target for promoting cardiac muscle contractility under various pathophysiological conditions, such as diabetic cardiomyopathy and heart failure.
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